Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Breaking & Recent News Edgewise Therapeutics Inc. EWTX

Edgewise Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of innovative treatments for severe, rare muscle disorders. It is developing orally bioavailable, small molecule therapies for musculoskeletal diseases.


Recent & Breaking News (NDAQ:EWTX)

Edgewise Therapeutics Announces Closing of Upsized Public Offering of Common Stock, Including Full Exercise of Underwriters' Option to Purchase Additional Shares

Business Wire 11 days ago

Edgewise Therapeutics Announces Pricing of Upsized Public Offering of Common Stock

Business Wire September 13, 2022

Edgewise Therapeutics Announces Proposed Offering of Common Stock

Business Wire September 13, 2022

Edgewise Therapeutics Announces Positive 4-Month Interim Results from the ARCH Open Label Study of EDG-5506 in Adults with Becker Muscular Dystrophy (BMD)

Business Wire September 11, 2022

Edgewise Therapeutics Announces FDA Authorization for Phase 2 Clinical Trial of EDG-5506 for the Treatment of Duchenne Muscular Dystrophy (DMD)

Business Wire September 7, 2022

Edgewise Therapeutics Reports Second Quarter 2022 Financial Results

Business Wire August 4, 2022

Edgewise Therapeutics to Present at the Wedbush PacGrow Healthcare Conference on August 9

Business Wire August 3, 2022

Edgewise Therapeutics Now Enrolling CANYON Phase 2 Clinical Trial of EDG-5506 in Individuals with Becker Muscular Dystrophy (BMD)

Business Wire July 12, 2022

Edgewise Therapeutics Announces Positive 2-Month Interim Results from the ARCH Open Label Study of EDG-5506 in Adults with Becker Muscular Dystrophy (BMD)

Business Wire June 20, 2022

New 2-Month Interim Data from the ARCH Open Label Study of EDG-5506 in Individuals with Becker Muscular Dystrophy (BMD) to be Presented at the Upcoming New Directions in Biology and Disease of Skeletal Muscle Conference

Business Wire June 16, 2022

Edgewise Therapeutics to Present at Upcoming Investor Conferences

Business Wire May 31, 2022

Edgewise Therapeutics Reports First Quarter 2022 Financial Results

Business Wire May 11, 2022

Edgewise Therapeutics to Present at Upcoming Investor Conferences

Business Wire May 3, 2022

Edgewise-Funded Natural History Trial of Becker Muscular Dystrophy (BMD) Now Enrolling

Business Wire April 14, 2022

Edgewise Therapeutics to Present on EDG-5506 for Becker and Duchenne Muscular Dystrophy (BMD, DMD) at the 2022 Annual MDA Clinical and Scientific Conference

Business Wire March 8, 2022

Edgewise Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results

Business Wire February 24, 2022

Edgewise Therapeutics to Participate at SVB Leerink 11th Annual Global Healthcare Conference on February 16

Business Wire February 2, 2022

Edgewise Therapeutics Announces Positive Topline Results From the EDG-5506 Phase 1b Clinical Trial in Adults With Becker Muscular Dystrophy (BMD)

Business Wire January 5, 2022

Edgewise Therapeutics to Report Phase 1b Topline Results of EDG-5506 in Individuals with Becker Muscular Dystrophy (BMD) on January 5, 2022, and Initiates ARCH Follow-On Open Label BMD Study

Business Wire December 15, 2021

Edgewise Therapeutics to Participate at Evercore ISI 4th Annual HEALTHCONx Conference on December 2

Business Wire November 17, 2021